🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,153 results for “Ou” Clear

  1. ELVN-001

    Enliven Therapeutics

    CML (Chronic Myelogenous Leukemia)

    phase 1 small molecule active

    1 trial

  2. Effect of Renal Impairment on Enpatoran Pharmacokinetics

    Merck Sharp and Dohme

    Healthy volunteers and patients with renal impairment; Intended indication: autoimmune diseases; systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE), as well as dermatomyositis (DM) and polymyositis (PM).

    phase 1 other active

    1 trial

  3. Esketamine injection group (0.25 mg/kg)

    The First People's Hospital of Lianyungang

    Esketamine

    phase 1 small molecule active

    1 trial

  4. Evaluation of safety, side effects and how the drug CHF6467 administrated via intranasal route is absorbed, modified and removed in healthy subjects.

    Chiesi Farmaceutici S.p.A

    Neonatal Hypoxic-Ischemic Encephalopathy (HIE), Neonatal Hypoxic-Ischemic Encephalopathy (HIE)

    phase 1 other active

    1 trial

  5. Evaluation of the CHF 5993 concentration in blood, after inhalation with two different devices, (NEXThaler® versus pMDI), with and without Aerochamber spacer device, in healthy volunteers.

    Chiesi Farmaceutici S.p.A

    Asthma

    phase 1 other active

    1 trial

  6. Evaluation of the effect of CHF6795 on the pharmacokinetics of midazolam, repaglinide and rosuvastatin in healthy subjects

    Chiesi Farmaceutici S.p.A

    Chronic cough

    phase 1 other active

    1 trial

  7. Ex-vivo expanded allogeneic γδ T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    AML (Acute Myelogenous Leukemia)

    phase 1 mab active

    1 trial

  8. FT516

    Zafatek

    Acute Myelogenous Leukemia

    phase 1 small molecule terminated

    1 trial

  9. Febuxostat XR

    Takeda

    Gout

    phase 1 small molecule completed

    1 trial

  10. Fecal Microbiota Transplant (FMT)

    MAIA Biotechnology

    Chronic Pouchitis

    phase 1 small molecule active

    1 trial

  11. Fecal Microbiota Transplantation

    Finch Therapeutics Group

    Enterobacteriaceae Infections

    phase 1 mab terminated

    1 trial

  12. Fexofenadine Hydrochloride without sodium lauryl sulfate

    BRIGHT MINDS BIOSCIENCES INC.

    The Impact of Excipients on Drug Absorption

    phase 1 small molecule completed

    1 trial

  13. Four naloxone nasal spray doses (1 every 2.5 min)

    BRIGHT MINDS BIOSCIENCES INC.

    Healthy Subjects

    phase 1 small molecule completed

    1 trial

  14. GC4419

    Galera Therapeutics

    Squamous Cell Carcinoma of the Oral Cavity

    phase 1 small molecule completed

    1 trial

  15. GDC-0084

    KAZIA THERAPEUTICS LTD

    Brain and Central Nervous System Tumors

    phase 1 small molecule completed

    1 trial

  16. GPRC5D CAR-T cell intravenous infusion

    The First People's Hospital of Lianyungang

    Plasma Cell Dyscrasias

    phase 1 mab active

    1 trial

  17. GRT-1C102: A randomized, double-blind, placebo-controlled dose escalation study to evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics of GRT-001 after subcutaneous administrations to healthy subjects (MONOSqut trial).

    Rani Therapeutics Holdings

    Ulcerative colitis

    phase 1 other active

    1 trial

  18. GSK525762

    GlaxoSmithKline

    Solid Tumours

    phase 1 small molecule terminated

    1 trial

  19. Gemtuzumab Ozogamicin

    Jazz Pharmaceuticals Ireland Limited

    Acute Myelogenous Leukemia

    phase 1 small molecule terminated

    1 trial

  20. Group 1: 10 ug FMP012 with 2 ug GLA-SE

    United Therapeutics Europe Ltd

    Malaria

    phase 1 mab completed

    1 trial

  21. Group A

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Colorectal Cancer

    phase 1 mab active

    1 trial

  22. Group A

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma

    phase 1 mab active

    1 trial

  23. Group A Deactivated TENS with beeping sound (15-second interval)

    United Therapeutics Europe Ltd

    Healthy

    phase 1 other completed

    1 trial

  24. HEC93077

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Gout

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources